Antileukemic activity of valproic acid in chronic lymphocytic leukemia B cells defined by microarray analysis.
about
Molecular and therapeutic potential and toxicity of valproic acidHistone deacetylases mediate the silencing of miR-15a, miR-16, and miR-29b in chronic lymphocytic leukemiaTrials with 'epigenetic' drugs: an updateA new gene selection procedure based on the covariance distance.The histone deacetylase inhibitor suberoylanilide hydroxamic acid induces apoptosis, down-regulates the CXCR4 chemokine receptor and impairs migration of chronic lymphocytic leukemia cellsInteraction networks of lithium and valproate molecular targets reveal a striking enrichment of apoptosis functional clusters and neurotrophin signalingAMD3100 disrupts the cross-talk between chronic lymphocytic leukemia cells and a mesenchymal stromal or nurse-like cell-based microenvironment: pre-clinical evidence for its association with chronic lymphocytic leukemia treatments.Histone deacetylase inhibitors: clinical implications for hematological malignancies.Analyzing gene expression profile in K562 cells exposed to sodium valproate using microarray combined with the connectivity map databaseGlobal histone deacetylase enzymatic activity is an independent prognostic marker associated with a shorter overall survival in chronic lymphocytic leukemia patientsDysregulation of autophagy in chronic lymphocytic leukemia with the small-molecule Sirtuin inhibitor Tenovin-6.Treatment options for high-risk chronic lymphocytic leukaemia.Using an exon microarray to identify a global profile of gene expression and alternative splicing in K562 cells exposed to sodium valproate.Synergistic apoptotic response between valproic acid and fludarabine in chronic lymphocytic leukaemia (CLL) cells involves the lysosomal protease cathepsin BCharacterization of TET and IDH gene expression in chronic lymphocytic leukemia: comparison with normal B cells and prognostic significanceValproic acid for the treatment of malignant gliomas: review of the preclinical rationale and published clinical results.The Histone Deacetylase Inhibitor Valproic Acid Sensitizes Gemcitabine-Induced Cytotoxicity in Gemcitabine-Resistant Pancreatic Cancer Cells Possibly Through Inhibition of the DNA Repair Protein Gamma-H2AX.A hearty solution for acute myeloid leukemia.Cross-talk between DNA methylation and active histone modifications regulates aberrant expression of ZAP70 in CLL.Bortezomib induces apoptosis in T lymphoma cells and natural killer lymphoma cells independent of Epstein-Barr virus infection.HDAC isoenzyme expression is deregulated in chronic lymphocytic leukemia B-cells and has a complex prognostic significance.Extracellular vesicles of bone marrow stromal cells rescue chronic lymphocytic leukemia B cells from apoptosis, enhance their migration and induce gene expression modifications.Valproic acid enhances fludarabine-induced apoptosis mediated by ROS and involving decreased AKT and ATM activation in B-cell-lymphoid neoplastic cells.
P2860
Q21296867-383F36A6-E535-41EF-BB43-5004966C7581Q24633394-0A69F4A9-2569-4AED-8DB4-865107FA73C9Q27000542-1E8CEEAC-7E96-4372-B282-1349EB996F66Q33627569-293D4D5F-7073-48D5-831D-63447701C01DQ33952785-B08B942D-5C8C-415B-9813-547582EDBC84Q35100070-4FF2A5B2-05F1-4C47-A1AF-E7F8F11B9799Q35944653-8385B524-518C-4A43-BB6B-56FB959F1DDCQ36001847-C4DB35F4-3F41-48BC-85E0-A47CFDE2B045Q36026603-B9432A67-C059-4FD0-A410-91D0212DE8A6Q36212773-3DC13BC8-0B8D-4371-BF6B-DF8655D0B72BQ36609978-848A7B68-9AFF-486D-8BB1-6CE365B51523Q36612587-DD911617-E830-4F8E-83D6-4C2D9C7631C0Q36642277-BE87FCEA-EE92-4945-B649-8A9326EFE728Q37275725-E864FCA1-FBBC-4465-8154-89EBB741EA02Q37480308-75EEEBA5-2E6D-46CB-8E95-1B8D82CF4088Q38016227-A62B3EAB-D8D8-4E4C-92BF-CE134D296924Q38879058-F1C737B3-1EBA-4114-8109-CF21E79B0A33Q39234420-4E6D989C-395A-4C8C-A4F6-0C18C6F27A87Q39431594-8A77BF34-36CF-4760-8B40-8FAC60C1CCA4Q39618066-37DAF07C-8A2E-49FD-825E-0FEF52D673DBQ42426152-7482280B-6AE9-4E13-B764-64C6E72BFAB6Q45083622-A09A95A9-9526-4700-8039-4EAA93784226Q54407620-894AA3C8-EC79-471D-A155-F9F6820BCA24
P2860
Antileukemic activity of valproic acid in chronic lymphocytic leukemia B cells defined by microarray analysis.
description
2009 nî lūn-bûn
@nan
2009年の論文
@ja
2009年学术文章
@wuu
2009年学术文章
@zh
2009年学术文章
@zh-cn
2009年学术文章
@zh-hans
2009年学术文章
@zh-my
2009年学术文章
@zh-sg
2009年學術文章
@yue
2009年學術文章
@zh-hant
name
Antileukemic activity of valpr ...... efined by microarray analysis.
@en
Antileukemic activity of valpr ...... efined by microarray analysis.
@nl
type
label
Antileukemic activity of valpr ...... efined by microarray analysis.
@en
Antileukemic activity of valpr ...... efined by microarray analysis.
@nl
prefLabel
Antileukemic activity of valpr ...... efined by microarray analysis.
@en
Antileukemic activity of valpr ...... efined by microarray analysis.
@nl
P2093
P2860
P356
P1433
P1476
Antileukemic activity of valpr ...... efined by microarray analysis.
@en
P2093
B Stamatopoulos
C De Bruyn
L Lagneaux
N Meuleman
P2860
P2888
P304
P356
10.1038/LEU.2009.176
P577
2009-08-27T00:00:00Z
P5875
P6179
1033489705